Pipeline Overview
| Product | Mechanism | Ownership | Indication | Preclinical | Clinical Proof-of-Concept | Pivotal |
|---|---|---|---|---|---|---|
| HM43239 | Myeloid Kinome | Aptose WW | AML |
complete
AML
Preclinical Phase complete
|
in progress
Clinical Proof-of-Concept Phase in progress
|
not started
Pivotal Phase not started
|
| Luxeptinib | Lymphoid Kinome | Aptose: WW Crystal Genomics: Korea |
CLL & NHL |
complete
CLL & NHL
Preclinical Phase complete
|
in progress
Clinical Proof-of-Concept Phase in progress
|
not started
Pivotal Phase not started
|
| Luxeptinib | Myeloid Kinome | Aptose: WW Crystal Genomics: Korea |
AML & MDS |
complete
AML & MDS
Preclinical Phase complete
|
in progress
Clinical Proof-of-Concept Phase in progress
|
not started
Pivotal Phase not started
|
| APTO-253 | MYC | Aptose: WW | AML & MDS |
complete
AML & MDS
Preclinical Phase complete
|
in progress
Clinical Proof-of-Concept Phase in progress
|
not started
Pivotal Phase not started
|
| APL-581 | BRD4/JAK | Aptose and Ohm | Hematologic Cancers |
in progress
Hematologic Cancers
Preclinical Phase in progress
|
not started
Clinical Proof-of-Concept Phase not started
|
not started
Pivotal Phase not started
|
Luxeptinib for B-cell Tumors
Oral, Mutation-Agnostic, Dual Lymphoid / Myeloid Kinome Inhibitor (LKI/MKI)
Luxeptinib is being developed for the treatment of patients with certain B-cell malignancies, including chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and certain non-Hodgkin’s lymphomas (NHL) who are resistant or intolerant to conventional treatments.
View Candidate
Luxeptinib for Myeloid Tumors
Oral, Mutation-Agnostic, Dual Lymphoid / Myeloid Kinome Inhibitor (LKI/MKI)
Luxeptinib is also being developed for the treatment of patients with relapsed or refractory acute myeloid leukemia (AML), including the emerging populations resistant to approved targeted therapies.
View Candidate
HM43239 for Myeloid Tumors
Oral, Potent Myeloid Kinome Inhibitor (MKI)
HM43239 is being developed for the treatment of patients with relapsed or refractory acute myeloid leukemia (AML).
View Candidate
Posters & Presentations
Our online library includes numerous publications, including presentations, posters, and other media that provide additional information on preclinical and clinical studies of our drug candidates.
View Posters & Presentations